What is Normunity?
Normunity is a biotechnology company dedicated to creating novel anti-cancer therapies. The company's approach addresses untapped biological mechanisms at the interface of the immune system and the tumor, aiming to target factors that influence tumor growth and circumvent immune surveillance. Normunity is building a pipeline of anti-cancer medicines, including therapeutic antibodies, bispecific antibodies, and payload-carrying biologics. Its lead program, NRM823, is a T cell engager designed for multiple solid tumors and is slated for clinical entry in 2025. The company operates across Boston, MA, and New Haven, CT, with its online presence at www.normunity.com.
How much funding has Normunity raised?
Normunity has raised a total of $140M across 2 funding rounds:
Series A
$65M
Series B
$75M
Series A (2022): $65M with participation from Sanofi Ventures, Osage University Partners, investorCanaan Ventures, and Taiho Ventures
Series B (2025): $75M led by Connecticut Innovations, Sanofi Ventures, Enavate Sciences, Osage Venture Partners, Taiho Ventures, Regeneron Ventures, Samsara BioCapital, Canaan Partners, YK, and Pfizer
Key Investors in Normunity
Connecticut Innovations
Connecticut Innovations is Connecticuts strategic venture capital arm and quasipublic investment agency, providing equity and debt financing, strategic guidance, and connections to help innovative, growing companies in the state scale, with dedicated funds for sectors like AI/quantum, climate tech, and biosciences.
Sanofi Ventures
Sanofi Ventures is the corporate venture capital arm of Sanofi. Sanofi Ventures invests in early-stage biotech and digital health companies with innovative ideas and transformative new products and technologies of strategic interest to Sanofi. Among these areas are oncology, immunology, rare diseases, vaccines, potential cures in other core areas of Sanofi's business footprint, and digital health solutions. Find out more: www.sanofiventures.com.
Enavate Sciences
Enavate Sciences is committed to invest in and support the strategic growth of innovative therapeutic and enabling technology companies that have the potential to transform patient care and improve quality of life. The company consider a broad range of therapeutic areas being developed at both pre-clinical and clinical stage companies, prioritizing growth potential and areas of unmet medical need.
What's next for Normunity?
The recent major strategic investment signifies a critical growth phase for Normunity, likely enabling the advancement of its lead program, NRM823, into clinical trials and further pipeline development. This capital infusion will support the company's mission to translate its novel targets into effective anti-cancer medicines. The backing from prominent investors suggests confidence in Normunity's scientific approach and its potential to address significant unmet needs in oncology. Future developments will likely focus on clinical trial execution, potential regulatory milestones, and further expansion of its therapeutic portfolio.
See full Normunity company page
